Case control study of rotavirus vaccine effectiveness in Portugal during 6 years of private market use

Pediatric Infectious Disease Journal

Volumn 34, Issue 5, 2015, Pages 509-512

  Marlow, Robin ^a,b   Ferreira, Muriel ^c   Cordeiro, Eugénio ^d   Trotter, Caroline ^e   Januário, Luis ^c   Finn, Adam ^a,b   Rodrigues, Fernanda ^c,f  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d Administração Regional de Saúde do Centro   (Portugal)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

case control; pediatric; rotavirus; vaccine; vaccine effectiveness

Indexed keywords

ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; ARTICLE; CASE CONTROL STUDY; CHILD; CHILDHOOD DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MARKETING; DRUG USE; FECES ANALYSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PEDIATRIC HOSPITAL; PORTUGAL; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS INFECTION; VACCINATION; VIRAL GASTROENTERITIS; GASTROENTERITIS; IMMUNOLOGY; NEWBORN; ROTAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FEMALE; GASTROENTERITIS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PORTUGAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 84937514159     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000647     Document Type: Article

References (22)

1. Marlow RD, Finn A. The promise of immunisation against rotavirus. Arch Dis Child. 2012; 97: 736-740
2. Vesikari T, Karvonen AV, Majuri J, et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis. 2006; 194: 370-376
3. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Human Rotavirus Vaccine Study Group Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006; 354: 11-22
4. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010; 362: 289-298
5. Armah GE, Breiman RF, Tapia MD, et al. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine. 2012; 30(suppl 1): A86-A93
6. WHO. Global Advisory Committee on Vaccine Safety, Report of meeting held 17-18 June 2009. Available from: http://www.who.int/vaccine-safety/Jun-2009/en. Accessed July 16, 2014
7. WHO vaccine-preventable diseases: monitoring system. 2014 global summary. Available from: http://apps.who.int/immunization-monitoring/globalsummary/schedules. Accessed July 16, 2014
8. Jit M, Bilcke J, Mangen MJ, et al. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine. 2009; 27: 6121-6128
9. Parez N, Giaquinto C, Du Roure C, et al. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis. 2014; 14: 416-425
10. Sociedade Portuguesa de Pediatria. Recomendações para a vacina contra rotavírus. Available from: http://www.spp.pt/UserFiles/file/Publicacoes/RV-Recomendacoes-09-final%5B1%5D.pdf. Accessed July 16, 2014
11. Rodrigues F, Iturriza-Gómara M, Marlow R, et al. The evolving epidemiology of rotavirus gastroenteritis in central Portugal with modest vaccine coverage. J Clin Virol. 2013; 56: 129-134
12. World Health Organization. Department of Immunization V and B. Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. Available from: http://www.who.int/immunization/documents/WHO-IVB-08.16/en. Accessed July 16, 2014
13. R Core Team. R: a language and environment for statistical computing; 2014. Available from: http://www.r-project.org. Accessed July 16, 2014
14. Hansen BB, Klopfer SO. Optimal full matching and related designs via network flows. J Comput Graph Stat. 2006; 15: 609-627
15. Braeckman T, Van Herck K, Meyer N, et al. RotaBel Study Group Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ. 2012; 345: e4752
16. Paulke-Korinek M, Kollaritsch H, Aberle SW, et al. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. Vaccine. 2013; 31: 2686-2691
17. Vesikari T, Uhari M, Renko M, et al. Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland. Pediatr Infect Dis J. 2013; 32: 1365-1373
18. Bellido-Blasco JB, Sabater-Vidal S, Salvador-Ribera Mdel M, et al. Rotavirus vaccination effectiveness: a case-case study in the EDICS project, Castellón (Spain). Vaccine. 2012; 30: 7536-7540
19. Castilla J, Beristain X, Martínez-Artola V, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine. 2012; 30: 539-543
20. Martinón-Torres F, Bouzón Alejandro M, Redondo Collazo L, et al. ROTACOST Research Team Effectiveness of rotavirus vaccination in Spain. Hum Vaccin. 2011; 7: 757-761
21. Adlhoch C, Hoehne M, Littmann M, et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010 2011. Pediatr Infect Dis J. 2013; 32: e82-e89
22. Ferreira M, Marlow R, Barreto I, et al. Changes in the epidemiology of rotavirus acute gastroenteritis (RVAG) over seven years of vaccine use in Portugal. 32nd Annual Meeting European Society of Paediatric Infectious Diseases; Dublin, Ireland, 2014. Abstract 464 (PO19A